News coverage about Syros Pharmaceuticals (NASDAQ:SYRS) has trended somewhat positive this week, according to Accern Sentiment Analysis. The research group scores the sentiment of press coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Syros Pharmaceuticals earned a news sentiment score of 0.11 on Accern’s scale. Accern also gave news coverage about the company an impact score of 45.8883342397851 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
A number of research analysts have recently commented on SYRS shares. Oppenheimer set a $28.00 price target on shares of Syros Pharmaceuticals and gave the company a “buy” rating in a research report on Wednesday, December 13th. Cowen restated a “buy” rating on shares of Syros Pharmaceuticals in a research report on Monday, December 11th. Zacks Investment Research upgraded shares of Syros Pharmaceuticals from a “hold” rating to a “buy” rating and set a $11.00 target price for the company in a research report on Friday, January 5th. HC Wainwright reiterated a “hold” rating and issued a $10.00 target price on shares of Syros Pharmaceuticals in a research report on Thursday, December 21st. Finally, Roth Capital assumed coverage on shares of Syros Pharmaceuticals in a research report on Monday, October 23rd. They issued a “neutral” rating and a $15.00 target price for the company. One analyst has rated the stock with a sell rating, three have given a hold rating and six have assigned a buy rating to the company’s stock. Syros Pharmaceuticals currently has an average rating of “Buy” and an average target price of $22.36.
Syros Pharmaceuticals (NASDAQ:SYRS) traded down $0.15 during trading on Wednesday, reaching $10.24. 152,421 shares of the company’s stock traded hands, compared to its average volume of 324,393. The company has a market capitalization of $269.28 and a P/E ratio of -5.89. Syros Pharmaceuticals has a 1-year low of $6.30 and a 1-year high of $24.38.
Syros Pharmaceuticals (NASDAQ:SYRS) last issued its quarterly earnings data on Wednesday, November 8th. The company reported ($0.53) EPS for the quarter, meeting the consensus estimate of ($0.53). equities research analysts forecast that Syros Pharmaceuticals will post -2.12 EPS for the current year.
In related news, insider Jeremy P. Springhorn purchased 15,000 shares of the firm’s stock in a transaction that occurred on Friday, December 15th. The stock was bought at an average cost of $9.08 per share, with a total value of $136,200.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Srinivas Akkaraju purchased 109,774 shares of the firm’s stock in a transaction that occurred on Thursday, December 14th. The stock was bought at an average cost of $9.03 per share, with a total value of $991,259.22. The disclosure for this purchase can be found here. Over the last ninety days, insiders have bought 334,198 shares of company stock valued at $3,127,458. Insiders own 33.60% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Syros Pharmaceuticals (NASDAQ:SYRS) Getting Somewhat Positive News Coverage, Analysis Finds” was first published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this news story on another publication, it was copied illegally and reposted in violation of United States & international copyright and trademark laws. The legal version of this news story can be viewed at https://www.dispatchtribunal.com/2018/02/14/syros-pharmaceuticals-syrs-getting-somewhat-positive-news-coverage-study-shows-3.html.
Syros Pharmaceuticals Company Profile
Syros Pharmaceuticals, Inc is a biopharmaceutical company. The Company offers a gene control platform designed to analyze the unexploited region of deoxyribonucleic acid (DNA) in human disease tissue to identify and drug targets linked to genomically defined patient populations. The Company is focused on developing treatments for cancer and immune-mediated diseases and is building a pipeline of gene control medicines.
Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.